Search
Sunday 31 January 2016
  • :
  • :

Biotechnology Stocks News Analysis: XOMA (NASDAQ:XOMA), Retrophin (NASDAQ:RTRX), Orexigen Therapeutics, (NASDAQ:OREX)

Biotechnology Stocks News Analysis: XOMA (NASDAQ:XOMA), Retrophin (NASDAQ:RTRX), Orexigen Therapeutics, (NASDAQ:OREX)

– in Business & Finance

0

On Wednesday, XOMA Corp (NASDAQ:XOMA)’s shares declined -6.49% to $1.73.

XOMA offered -55.90% EPS for prior five years. The company has 450.30% return on equity value while its ROI ratio was -213.00%. The company has $219.38 million market capitalizations and the institutional ownership was 53.80%. Volatility of the stock was 18.67% for the week while for the month booked as 11.45%.

The mean estimate for the short term price target for XOMA Corp (NASDAQ:XOMA) stands at $2.30 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $6.00 while the lower price target estimate is at $1.00.

Analysts mean recommendation for the stock is 2.70. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta).

Retrophin Inc (NASDAQ:RTRX)’s shares dropped -13.38% to $18.90.

RTRX has beta value of 12.45. The company has the market capitalization of $779.98 billion. Return on assets ratio of the company was -12.30% while its return on equity ratio was -50.90%. ATR value of company was 1.89 while stock volatility for week was 10.17% while for month was 8.99%. Debt to equity ratio of the company was -0.56 and its current ratio was 1.40.

The mean estimate for the short term price target for Retrophin Inc (NASDAQ:RTRX) stands at $39.00 according to 2 Analysts. The higher price target estimate for the stock has been calculated at $48.00 while the lower price target estimate is at $30.00.

Analysts mean recommendation for the stock is 1.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Retrophin, Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and life-threatening diseases.

At the end of Wednesday’s trade, Orexigen Therapeutics, Inc. (NASDAQ:OREX)‘s shares surged 0.61% to $3.29.

OREX has market value of $410.04 billion while its EPS was booked as $-0.23 in the last 12 months. The stock has 125.39 million shares outstanding while 88.10% shares of the company were owned by institutional investors. In the profitability analysis, the company has gross profit margin of -43.80%. Beta value of the company was 2.63; beta is used to measure riskiness of the security.

The mean estimate for the short term price target for Orexigen Therapeutics, Inc. (NASDAQ:OREX) stands at $9.00 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $11.00 while the lower price target estimate is at $8.00.

Analysts mean recommendation for the stock is 1.70. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.